As of
Aug 14, 2026
2 days ago
AMGN Equity Research — HOLD — August 2026
Amgen (AMGN) Stock Analysis
Research note — not an order or personalized advice.
Health Care
Desk command · AMGN
12M
HOLD
Tactical
HOLD
PM
HOLD
Desk
Full
QC
Pass
Risk not statedInvalidation not stated
Research note — not a trade. This packet is an equity-research record. It is not an order, fill, best-execution instruction, or personalized investment advice.
AMGN note · Aug 14, 2026
25 min
Catalyst watch
Post-Q2 coverage is constructive on valuation (fair value lift to US$371.93; ~37% claimed gap to DCF value), but durability of the growth/pipeline story remains the contested question.
Price chart · AMGN
TradingView context — not part of the rating contract.
Tactical process check · 5D
—Neutral (HOLD unscored)Peer 54pExpandCollapse
Tactical process check · 5D
—Neutral (HOLD unscored)Peer 54p
Grading rule: ages the trader TACTICAL_RATING over 5 close-to-close sessions. BUY/OVERWEIGHT is Correct when the path is > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. This is not a 12-month thesis grade · context vs SPY. Scorecard computed 2026-08-15T18:08:48.506342+00:00.
5D move
—
2026-08-14 → awaiting
Outcome
Neutral (HOLD unscored)
5D trend
+1.04%
Vol (20D ann.)
+26.80%
vs SPY: +0.64%
Close 415.21 → — (USD, vendor closes)
Batch scorecard · 2026-08-14 · AMGN
Publish QC
passedExpandCollapse
Publish QC
passed
Pipeline fingerprint 4ce21d14d87e1d20
Trace 0a5e307b…
No QC issues recorded.